Intercell
| Company type | Aktiengesellschaft |
|---|---|
| WBAG: ICLL OTCQX: INRLY | |
| Industry | Biotechnology |
| Founded | 1998 |
| Defunct | 2013 |
| Fate | Merged with Vivalis SA |
| Successor | Valneva SE |
| Headquarters | , |
Key people | Thomas Lingelbach (CEO), Michel Gréco (Chairman of the supervisory board) |
| Products | Development of vaccines |
| Revenue | €34.2 million (2010) |
| (€251.2 million) (2010) | |
| (€255.2 million) (2010) | |
| Total assets | €225.2 million (end 2010) |
| Total equity | €121.1 million (end 2010) |
Number of employees | 410 (average, 2010) |
| Website | www |
Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012. Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna. It employs 400 people in Austria, Scotland and the United States.